Diabetes : intravitreous ranibizumab for proliferative diabetic retinopathy

Jonathan M. Gibson; Samantha McGinnigle

doi:10.1038/nrendo.2016.1

Diabetes : intravitreous ranibizumab for proliferative diabetic retinopathy

Jonathan M. Gibson^*
, Samantha McGinnigle

^*Corresponding author for this work

Research output: Contribution to journal › Letter, comment/opinion or interview › peer-review

4 Citations (Scopus)

Abstract

The Diabetic Retinopathy Clinical Research Network has published the 2-year results of a 5-year study comparing intravitreous ranibizumab with panretinal laser photocoagulation in patients with proliferative diabetic retinopathy. The results suggest that intravitreous ranibizumab will become a valuable treatment option, although its exact role remains to be defined.

Original language	English
Pages (from-to)	130-131
Number of pages	2
Journal	Nature Reviews Endocrinology
Volume	12
Issue number	3
DOIs	https://doi.org/10.1038/nrendo.2016.1
Publication status	Published - 22 Jan 2016

Bibliographical note

-

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

diabetes complications
drug therapy
eye diseases

Access to Document

10.1038/nrendo.2016.1

Cite this

@article{068eb32449464b388df27ed03f09894f,

title = "Diabetes : intravitreous ranibizumab for proliferative diabetic retinopathy",

abstract = "The Diabetic Retinopathy Clinical Research Network has published the 2-year results of a 5-year study comparing intravitreous ranibizumab with panretinal laser photocoagulation in patients with proliferative diabetic retinopathy. The results suggest that intravitreous ranibizumab will become a valuable treatment option, although its exact role remains to be defined.",

keywords = "diabetes complications, drug therapy, eye diseases",

author = "Gibson, \{Jonathan M.\} and Samantha McGinnigle",

note = "-",

year = "2016",

month = jan,

day = "22",

doi = "10.1038/nrendo.2016.1",

language = "English",

volume = "12",

pages = "130--131",

journal = "Nature Reviews Endocrinology",

issn = "1759-5029",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Diabetes : intravitreous ranibizumab for proliferative diabetic retinopathy

AU - Gibson, Jonathan M.

AU - McGinnigle, Samantha

N1 - -

PY - 2016/1/22

Y1 - 2016/1/22

N2 - The Diabetic Retinopathy Clinical Research Network has published the 2-year results of a 5-year study comparing intravitreous ranibizumab with panretinal laser photocoagulation in patients with proliferative diabetic retinopathy. The results suggest that intravitreous ranibizumab will become a valuable treatment option, although its exact role remains to be defined.

AB - The Diabetic Retinopathy Clinical Research Network has published the 2-year results of a 5-year study comparing intravitreous ranibizumab with panretinal laser photocoagulation in patients with proliferative diabetic retinopathy. The results suggest that intravitreous ranibizumab will become a valuable treatment option, although its exact role remains to be defined.

KW - diabetes complications

KW - drug therapy

KW - eye diseases

UR - https://www.scopus.com/pages/publications/84958109950

UR - https://www.nature.com/articles/nrendo.2016.1

U2 - 10.1038/nrendo.2016.1

DO - 10.1038/nrendo.2016.1

M3 - Letter, comment/opinion or interview

C2 - 26794438

AN - SCOPUS:84958109950

SN - 1759-5029

VL - 12

SP - 130

EP - 131

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

IS - 3

ER -

Diabetes : intravitreous ranibizumab for proliferative diabetic retinopathy

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this